CAC Nantong Chemical Co Ltd

CAC Nantong Chemical Co Ltd

301665.SZ
CAC Nantong Chemical Co LtdCN flagShenzhen Stock Exchange
23.30
CNY
-0.64
- -
10.49BMarket Cap
CAC Nantong Chemical Co Ltd
301665.SZ
(Shenzhen Stock Exchange)

Recent

price

23.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.31
5.95
7.68
7.54
8.81
12.57
9.6
10.51
12.33
11.35
Revenue per Share
0.33
0.96
1.31
0.97
0.98
1.6
0.86
0.66
1.07
0.83
Basic EPS, GAAP
0.14
0.6
0.75
0.46
-0.97
-0.33
-0.56
-1.43
-0.21
-0.69
Free Cash Flow per Basic Share
0.25
0.18
0.46
0.85
0.12
0.93
0.18
0.16
0.79
0.52
Dividend per Share
1.5
2.34
3.18
3.28
4.2
4.97
5.73
6.35
6.4
6.31
Book Value per Share
1.83
3.01
4.51
4.57
5.6
6.45
7.31
8.07
8.71
8.97
Tangible Book Value per Share
408
403
404
405
406
406
403
403
435
413
Basic Weighted Avg Shares
1,759
2,396
3,105
3,058
3,579
5,099
3,868
4,236
5,369
4,690
Sales/Revenue/Turnover
15.94
25.31
29.39
22.3
15.3
17.04
11.23
9.68
14.5
7.33
Operating Margin (%)
87
94
122
144
160
202
222
241
259
- -
Depreciation Expense
135
387
530
393
398
649
346
266
466
342
Net Income, GAAP
17.99
16.37
15.26
13.91
10.72
14.03
11.48
10.14
13.19
11.04
Effective Tax Rate (%)
7.66
16.15
17.06
12.86
11.12
12.73
8.96
6.28
8.68
7.3
Profit Margin (%)
-144
51
500
197
420
659
402
636
735
1,084
Working Capital
104
67
208
168
272
328
396
500
335
607
LT Debt
879
1,338
1,952
2,043
2,471
2,823
3,165
3,463
4,152
3,922
Total Equity
- -
31.46
35.22
22.45
16.14
20.9
9.77
8.25
12.89
6.13
Return on Invested Capital (%)
- -
25.05
23.46
17.82
20.45
25.57
14.39
8.86
8.19
6.91
Return on Capital (%)
- -
49.67
47.55
30.09
26.23
34.89
16.01
10.92
17.42
13.63
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
947
1,019
1,030
LT Borrowings
500
551
607
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
405
450
450
Market Capitalization
- -
- -
12,590

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,236
2,456
2,744
Cash, Cash Equivalents & STI
504
455
963
Accounts Receivable, Net
1,000
1,063
970
Inventories
528
711
629
Total Current Liabilities
1,600
1,690
1,660
Payables & Accruals
- -
- -
- -
ST Debt
947
1,019
1,030
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.33%
19.87%
Free Cash Flow
- -
-47.7%
-84.28%
Net Income, GAAP
- -
13.91%
75.13%
Sales/Revenue/Turnover
- -
14.32%
26.73%
Total Cash Common Dividend
- -
185.27%
414.21%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
871
1,088
1,064
1,213
4,236
2025
1,033
1,380
1,478
- -
5,369
2026
1,378
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
- -
- -
- -
0.66
2025
0.19
- -
- -
- -
1.07
2026
0.3
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.16
2025
0.04
- -
- -
- -
0.79
2026
0.04
- -
- -
- -
- -
Business
CAC Nantong Chemical Co Ltd (301665.SZ) manufactures and sells specialty chemical products, primarily focusing on pharmaceutical intermediates, pesticide intermediates, and fine chemicals. The company offers a range of products including 2,5-dichloronitrobenzene, 2-chloro-5-nitrobenzotrifluoride, 4-chloro-3-nitrobenzotrifluoride, 2,4-dichloro-5-nitrobenzotrifluoride, and other fluorinated and chlorinated aromatic compounds used in agrochemicals, pharmaceuticals, and dyes; it also provides custom synthesis services and contract manufacturing for chemical intermediates. Headquartered in Nantong, Jiangsu Province, China, the company was founded in 2003 and operates primarily in the domestic Chinese market with exports to Asia and Europe. In recent developments, CAC Nantong Chemical expanded its production capacity through a new facility in 2024 for fluorinated intermediates to meet growing demand in the pharmaceutical sector; it also formed a strategic partnership with a leading agrochemical firm in early 2025 for joint development of pesticide intermediates and secured a RMB 150 million funding round for technology upgrades. The company serves major producers in the agrochemical and pharmaceutical industries as its target customers, with no listed subsidiaries or parent relationships.